Health · global
Could Probiotics Become a Gentle Aid in Depression Treatment? Small Clinical Trial in Older Adults Offers Early Clues
A small randomized trial in India showed that adding a daily probiotic supplement to existing antidepressant treatment may give older adults with depression slightly greater improvement in mood and anxiety symptoms; however, the evidence remains preliminary and should not be interpreted as support for replacing medication or psychotherapy on one’s own.
The connection between the gut and mood has gradually moved in recent years from a fringe hypothesis into the field of clinical research. A pilot trial newly published in the Journal of the American Geriatrics Society examined this question in the care of depression in older adults: if daily probiotics are added to standard antidepressant treatment, will symptoms show a measurable difference?
The study enrolled 58 adults in India who were at least 60 years old and had moderate unipolar depression. All participants continued receiving their original standard antidepressant treatment and were randomly assigned in a 1:1 ratio to take either a probiotic supplement or an identical-looking placebo every day for 12 weeks; the research team then followed them for another 12 weeks to observe later changes.
The results showed that participants in both groups improved significantly during the study, an important point because it cautions against attributing all progress to probiotics. However, compared with placebo, the probiotic group had slightly larger reductions in depression and anxiety scores, leading the researchers to believe that probiotics may show some signal as an adjunctive treatment.
The study also attempted to connect clinical symptoms with biological clues. In addition to using depression and anxiety scales, the team measured serum brain-derived neurotrophic factor (BDNF) concentrations and conducted fecal microbiota analysis. BDNF is related to the growth, maintenance, and survival of nerve cells and is often used to explore the biological mechanisms of mood disorders; fecal microbiota can depict changes in the composition of gut bacteria.
But the study’s message should be understood at the proper scale. It was a small pilot, multicenter, double-blind, placebo-controlled trial, and its size was not sufficient to answer questions such as who is most likely to benefit, how long the effect can last, or whether different probiotic formulations make a difference. The study also did not show that probiotics produced a clearer overall improvement in quality of life compared with placebo.
From a clinical perspective, these findings are more like opening a door than providing a prescription. Depression in older adults is often accompanied by chronic disease, polypharmacy, and declining daily function, and any adjunctive strategy must take safety, interactions, and individual medical conditions into account; even if probiotics appear gentle, that does not mean they are suitable for everyone to add on their own.
The next key question is whether larger trials can reproduce this effect and further disentangle whether the relationships among gut microbiota, BDNF, and symptom improvement are causal or accompanying changes. If later evidence becomes more robust, probiotics may have an opportunity to become a low-burden adjunctive tool in the care of depression in older adults; until then, they should still be viewed as a biologically plausible research clue, not an established psychiatric treatment option.